Barriers to Recruitment in Pediatric Obesity Trials: Comparing Opt-in and Opt-out Recruitment Approaches

Mary Beth McCullough1, David Janicke2, Cathleen Odar Stough1

  • 1Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Insights

Opt-out recruitment is more effective for preschool obesity trials than opt-in. This method increases participation by not requiring parents to recognize their child

Area of Science:

  • Pediatric Health
  • Clinical Trial Recruitment
  • Obesity Research

Background:

  • Pediatric weight management clinical trials face recruitment challenges.
  • Effective recruitment strategies are crucial for trial success and generalizability.
  • Understanding recruitment method efficacy is vital for optimizing trial participation.

Purpose of the Study:

  • To compare the effectiveness of opt-in versus opt-out recruitment strategies in pediatric weight management clinical trials.
  • To evaluate recruitment rates across different age groups (preschoolers vs. school-age children).

Main Methods:

  • Two randomized controlled trials (RCTs) for childhood obesity were analyzed.
  • Opt-in recruitment (parents initiate contact) was compared with opt-out recruitment (parents decline participation).
  • Recruitment rates were assessed for preschoolers and school-age children.

Main Results:

  • Opt-in strategies showed lower recruitment rates in preschoolers compared to school-age children.
  • For preschoolers, opt-out recruitment significantly increased overall recruitment rates compared to opt-in.
  • Opt-out strategies improved initial family contact rates in preschool trials.

Conclusions:

  • Opt-out recruitment may be more successful for preschool-aged children in obesity trials.
  • This method may circumvent barriers related to parental recognition of childhood obesity.
  • Implementing opt-out strategies could enhance participation in pediatric obesity research.
Abstract

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
201
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
647
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
357
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
313
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
520